Skip to Main Content

On Target is a new recurring feature from STAT that dives deep into the most promising drug targets in oncology. 

Of all the wily ways tumors have to turn back attacks from therapies or the immune system, an immune protein called TGF-beta may be one of the most curious.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!